“The pharmaceutical industry can have a hugely positive impact on our environment if we develop innovative solutions for manufacturing practices, and if we think in a more flexible and solutions-based approach,” organizers said.
James Choi, executive vice president, chief information and marketing officer at Samsung Biologics, will speak at the trade event on why pharmaceutical CDMOs should consider a shift in long-term sustainability.
He will explain how the pharmaceutical industry and innovative initiatives should work to improve outcomes for patients, employees, the environment and the wider community.
Aurelio Arias, IQVIA thought leadership engagement manager, said many health systems have identified medicines as one of the largest single contributors to their carbon footprint. His presentation at the Frankfurt trade fair will assess the carbon footprint of the pharmaceutical industry and offer advice on what the industry can do to reduce emissions, meet environmental goals and thus open up a new way to support human health.
Frank Roschangar, Distinguished Investigator, IU Sustainability, Boehringer Ingelheim Pharmaceuticals, and Michael Umberto Luescher, Process Development Chemist, Novartis Pharmaceuticals, are also discussing the topic.
They will discuss best practices for green chemistry metrics in the context of API life cycle assessment to assess the impact of waste on pharmaceutical raw material manufacturing and its limitations.
Pharmaceutical manufacturers must certify their excipient suppliers, and the International European Commission for Pharmaceutical Excipients (IPEC) has published the Excipient Information Package Guidelines (EIP) to support the industry.
Geertrui Haest, Cargill’s EMEA Regional Scientific and Regulatory Affairs Manager, representing IPEC, said that as the need for sustainability awareness grows, more and more suppliers are asking suppliers to provide evidence that they have an effective environmental, Social and governance (ESG) plans instead.
He will outline how new parts of the EIP will be developed to facilitate the exchange of ESG information. This includes an overview of the organization, ESG programs, procurement and supply chain, health and safety policies/practices, and business continuity plans.
The intersection of sustainability, quality and supply chain integrity
Rx-360 CEO Jim Fries to Provide Insights on Sustainability, Quality and Supply Chain Integrity in CPhI Presentation
He wants industry players to understand and challenge themselves to think about the intersection of sustainability, quality and supply chain integrity in the pharmaceutical industry.
“This relationship becomes very important as we move into a post-pandemic era, where the pharmaceutical industry strives not only to ensure the quality of its supply chain and materials, but also to ensure that it is sustainable to protect against shortages. This presentation will discuss three Opportunities for how departments can coordinate, and how best practices in one area can improve the other two.”
Sustainable Manufacturing in Developing Regions
Perrer Tosso, Senior Manager, Pharmaceutical Product Supply Services, USP, will discuss strategies for sustainable pharmaceutical manufacturing in low- and middle-income countries (LMICs) in a presentation at the German event.
He will reflect on the pharmaceutical supply chain vulnerabilities exposed by the Covid-19 pandemic, and efforts to expand local and regional production to include vaccines and active pharmaceutical ingredients, he will highlight the development of a new paradigm for sustainable pharmaceutical manufacturing, leveraging technology transfer, developing skilled workforce and install GMP compliant facilities.
He will also discuss key principles for achieving sustainable pharmaceutical production in low- and middle-income countries.
Diversity and Inclusion
Archana Bhaskar, Chief Human Resources Officer at Reddy’s Laboratories Ltd, will also speak on the topic of sustainability, which involves how pharmaceutical companies can enhance diversity, equity and inclusion in their operations.
“The pharmaceutical industry realizes it needs to increase the representation of women and minority communities in its operations. The benefits of a diverse team are obvious, but it’s not an easy path.
“Looking at diversity and inclusion as part of broader sustainability, ESG performance is an important indicator of pharmaceutical companies’ commitment to creating a more diverse and successful workplace, and ultimately ensuring better service for patients around the world. “